SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Operating Cash Flow
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (SHPH) reported Operating Cash Flow of -$2.98 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-09-24.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-09-24
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$567.64K.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$2.42M.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$973.01K.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$2.63M.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$9.48M.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$7.33M.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$5.58M.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$2.67M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | -$567.64K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-09-24 | -$2.98M 10-Q · filed 2026-09-24 | -$3.96M derived: sum of 3 quarters · filed 2026-09-24 | -$6.58M derived: sum of 4 quarters · filed 2026-09-24 | |
| 2026-03-31 | -$2.42M 10-Q · filed 2026-05-15 | -$3.39M derived: sum of 2 quarters · filed 2026-05-15 | -$6.02M derived: sum of 3 quarters · filed 2026-05-15 | -$9.37M derived: sum of 4 quarters · filed 2026-09-24 | |
| 2025-12-31 | -$973.01K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$3.60M derived: sum of 2 quarters · filed 2026-03-31 | -$6.95M derived: sum of 3 quarters · filed 2026-09-24 | -$9.48M 10-K · filed 2026-03-31 | |
| 2025-09-30 | -$2.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$5.98M derived: sum of 2 quarters · filed 2026-09-24 | -$8.51M 10-Q · filed 2025-11-13 | -$11.20M derived: sum of 4 quarters · filed 2026-09-24 | |
| 2025-06-30 | -$3.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-09-24 | -$5.88M 10-Q · filed 2026-09-24 | -$8.57M derived: sum of 3 quarters · filed 2026-09-24 | -$10.57M derived: sum of 4 quarters · filed 2026-09-24 | |
| 2025-03-31 | -$2.53M 10-Q · filed 2026-05-15 | -$5.22M derived: sum of 2 quarters · filed 2026-05-15 | -$7.22M derived: sum of 3 quarters · filed 2026-05-15 | -$8.62M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | -$2.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$4.69M derived: sum of 2 quarters · filed 2026-03-31 | -$6.09M derived: sum of 3 quarters · filed 2026-03-31 | -$7.33M 10-K · filed 2026-03-31 | |
| 2024-09-30 | -$2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$3.40M derived: sum of 2 quarters · filed 2025-11-13 | -$4.64M 10-Q · filed 2025-11-13 | -$5.70M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | -$1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$2.64M 10-Q · filed 2025-08-13 | -$3.70M derived: sum of 3 quarters · filed 2025-08-13 | -$5.24M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | -$1.24M 10-Q · filed 2025-05-08 | -$2.30M derived: sum of 2 quarters · filed 2025-05-08 | -$3.84M derived: sum of 3 quarters · filed 2025-05-08 | -$5.48M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | -$1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$2.60M derived: sum of 2 quarters · filed 2025-02-26 | -$4.24M derived: sum of 3 quarters · filed 2025-02-26 | -$5.58M 10-K · filed 2025-02-26 | |
| 2023-09-30 | -$1.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$3.18M derived: sum of 2 quarters · filed 2024-11-13 | -$4.52M 10-Q · filed 2024-11-13 | -$5.15M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | -$1.65M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-09-04 | -$2.98M 10-Q · filed 2024-09-04 | -$3.62M derived: sum of 3 quarters · filed 2024-09-04 | -$4.67M derived: sum of 4 quarters · filed 2024-09-04 | |
| 2023-03-31 | -$1.34M 10-Q/A · filed 2024-09-04 | -$1.97M derived: sum of 2 quarters · filed 2024-09-04 | -$3.02M derived: sum of 3 quarters · filed 2024-09-04 | -$3.38M derived: sum of 4 quarters · filed 2024-09-04 | |
| 2022-12-31 | -$635.82K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-09-04 | -$1.69M derived: sum of 2 quarters · filed 2024-09-04 | -$2.04M derived: sum of 3 quarters · filed 2024-09-04 | -$2.67M 10-K/A · filed 2024-09-04 | -$2.71M 10-K · filed 2023-03-15 |
| 2022-09-30 | -$1.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$1.41M derived: sum of 2 quarters · filed 2023-11-13 | -$2.03M 10-Q · filed 2023-11-13 | -$2.17M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | -$355.42K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$980.03K 10-Q · filed 2023-08-14 | -$1.12M derived: sum of 3 quarters · filed 2023-08-14 | ||
| 2022-03-31 | -$624.61K 10-Q · filed 2023-05-25 | -$759.76K derived: sum of 2 quarters · filed 2023-05-25 | |||
| 2021-12-31 | -$135.15K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | -$300.34K 10-K · filed 2023-03-15 | |||
| 2021-09-30 | -$165.19K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |